dacarbazine medac 1000 mg infuusiokuiva-aine, liuosta varten
medac gesellschaft fÜr klinische spezialprÄparate mbh - dacarbazine - infuusiokuiva-aine, liuosta varten - 1000 mg - dakarbatsiini
adrenalin aguettant 0.1 mg/ml injektioneste, liuos, esitäytetty ruisku
laboratoire aguettant - adrenaline tartrate - injektioneste, liuos, esitäytetty ruisku - 0.1 mg/ml - adrenaliini
lidocaine aristo 10 mg/ml injektioneste, liuos
aristo pharma gmbh - lidocaini hydrochloridum monohydricum - injektioneste, liuos - 10 mg/ml - lidokaiini
lidocaine aristo 20 mg/ml injektioneste, liuos
aristo pharma gmbh - lidocaini hydrochloridum monohydricum - injektioneste, liuos - 20 mg/ml - lidokaiini
nanogam 100 mg/ml infuusioneste, liuos
prothya biosolutions netherlands b.v. - human normal immunoglobulin - infuusioneste, liuos - 100 mg/ml - ihmisen normaali immunoglobuliini intravaskulaariseen käyttöön
adrenalin martindale pharma 0.1 mg/ml injektioneste, liuos
ethypharm - adrenaline tartrate - injektioneste, liuos - 0.1 mg/ml - adrenaliini
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektiiviset immunosuppressantit - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
bupropion accord 300 mg säädellysti vapauttava tabletti
accord healthcare b.v. - bupropion hydrochloride - säädellysti vapauttava tabletti - 300 mg - bupropioni
zenon 10 mg / 10 mg tabletti, kalvopäällysteinen
sanofi oy - rosuvastatinum calcicum,ezetimibum - tabletti, kalvopäällysteinen - 10 mg / 10 mg - rosuvastatiini ja etsetimibi
zenon 20 mg / 10 mg tabletti, kalvopäällysteinen
sanofi oy - ezetimibum,rosuvastatinum calcicum - tabletti, kalvopäällysteinen - 20 mg / 10 mg - rosuvastatiini ja etsetimibi